News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Agendia BV Announces Study Showing Molecular Subtyping Can Improve Breast Cancer Treatment


9/2/2014 11:05:49 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

IRVINE, Calif. and AMSTERDAM--(BUSINESS WIRE)--In findings that may eventually change the way breast cancer is evaluated and treated, a new study reports that the BluePrint genomic test provides more accurate information about the molecular subtype of a specific breast cancer, compared to the use of conventional IHC-FISH pathology tests.

The prospective observational study of 426 patients was recently published online by the Annals of Surgical Oncology. It concludes that the BluePrint assay may be a better guide than IHC-FISH tests in making decisions about how to treat early-stage breast cancer before surgery.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES